Nectar Lifescience Ltd

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 23 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Nectar Lifescience Ltd reported a flat financial performance for the quarter ended March 2026, marking a notable improvement from previous negative trends but still reflecting significant operational challenges. Despite a stabilisation in revenue growth, the company’s profitability metrics deteriorated sharply, underscoring persistent margin pressures in a competitive pharmaceutical sector.

Nectar Lifescience Ltd., a micro-cap pharmaceutical company specialising in cephalosporins, reported a devastating quarter-on-quarter deterioration in Q4 FY26, with consolidated net losses ballooning to ₹67.92 crores—a staggering 575.96% increase from the previous quarter's ₹14.27 crore profit. The company's standalone net loss stood at ₹37.21 crores, marking a catastrophic reversal from operational stability and raising serious questions about the viability of its business model.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Jul 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 29 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

At Rs 11.77, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

At Rs 14.91, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 9.96% on 7 May 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 13.56, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 9.98% on 7 May 2026, with buyers queuing and no sellers willing to part with shares.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and overall outlook.

At Rs 11.75, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 9.92% on 10 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 10.97, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 8.42% on 8 Apr 2026, with buyers queuing and no sellers willing to part with shares.